STAT reported Thursday that a Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week.

What does this early peek at the data tell us? What does it not tell us? And what comes next with clinical trials of remdesivir?

STAT senior writer Adam Feuerstein and Matthew Herper brief you on what’s known so far, and take questions from STAT Plus subscribers, in a live video chat.

advertisement

The video recording is embedded below.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy